Arthur Zelent
- Hematology top 0.2%
- Acute Myeloid Leukemia Research 58
- Biochemistry top 0.2%
- Antioxidant Activity and Oxidative Stress 9
- Molecular Biology top 0.5%
- Retinoids in leukemia and cellular processes 81
- Histone Deacetylase Inhibitors Research 29
- Protein Degradation and Inhibitors 24
- Epigenetics and DNA Methylation 14
- Ubiquitin and proteasome pathways 10
- Genetics top 0.5%
- Estrogen and related hormone effects 22
- Immunology top 2%
Arthur Zelent
124 papers receiving 10.2k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Hematology 2.9k
- Biochemistry 939
- Molecular Biology 8.8k
- Genetics 2.8k
- Immunology 1.3k
Countries citing papers authored by Arthur Zelent
This map shows the geographic impact of Arthur Zelent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Zelent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Zelent more than expected).
Fields of papers citing papers by Arthur Zelent
This network shows the impact of papers produced by Arthur Zelent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Zelent. The network helps show where Arthur Zelent may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Arthur Zelent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2023 | 9 | |
| 3 | 2022 | 17 | |
| 4 | 2022 | 17 | |
| 5 | 2021 | 32 | |
| 6 | 2020 | 132 | |
| 7 | 2019 | 29 | |
| 8 | 2016 | 39 | |
| 9 | 2009 | 79 | |
| 10 | 2007 | 174 | |
| 11 | 2007 | 76 | |
| 12 | 2005 | 90 | |
| 13 | 2005 | 13 | |
| 14 | Dithiophenes potentiate differentiation of APL cells by lowering the threshold for ligand mediated co-repressor/co-activator exchange with RAR alpha and enhancing changes in ATRA regulated gene expression. | 2003 | 1 |
| 15 | Rexinoid therapy bypasses the differentiation block associated with acute promyelocytic leukemia harboring the PLZF/RAR alpha rearrangement. | 2001 | 3 |
| 16 | 1998 | 149 | |
| 17 | 1994 | 31 | |
| 18 | Localization of the chromosome 15 breakpoints and expression of multiple PML-RAR alpha transcripts in acute promyelocytic leukemia: a study of 28 Chinese patients. | 1993 | 27 |
| 19 | 1988 | 7 | |
| 20 | 1988 | 25 |
About Arthur Zelent
Arthur Zelent is a scholar working on Hematology, Molecular Biology and Biochemistry, having authored 124 papers that have together received 10.4k indexed citations. Recurring topics across this work include Retinoids in leukemia and cellular processes (81 papers), Acute Myeloid Leukemia Research (58 papers), Histone Deacetylase Inhibitors Research (29 papers), Protein Degradation and Inhibitors (24 papers), Estrogen and related hormone effects (22 papers), Epigenetics and DNA Methylation (14 papers), Ubiquitin and proteasome pathways (10 papers) and Antioxidant Activity and Oxidative Stress (9 papers). The work is most often cited by research in Hematology (2.9k citations), Biochemistry (939 citations) and Molecular Biology (8.8k citations). Arthur Zelent has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Pierre Chambon, Martin Petkovich, A. Krust, Philippe Kastner, Samuel Waxman, Fabien Guidez, Andrée Krust, Jonathan D. Licht, Pier Paolo Pandolfi and Susannah Waxman. Their work appears in journals such as Blood, Proceedings of the National Academy of Sciences, Oncogene, Cancer Research and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.